AMH Rapid Test Device (Serum)

Anti-Müllerian Hormone is an important reproductive hormone. In females, AMH is produced by cells inside ovarian follicles. These follicles contain immature eggs, and AMH levels are often used as a snapshot of ovarian reserve. As age increases, the number of eggs naturally declines, and AMH levels also tend to decrease. The AMH Rapid Test Device (Serum) helps laboratories measure AMH levels using serum specimens.

The AMH Rapid Test Device (Serum) is intended for the professional in vitro diagnostic quantitative detection of Anti-Müllerian Hormone in human serum. It supports reproductive health evaluation, fertility assessment, ovarian reserve testing, IVF planning, and PCOS-related clinical assessment when used with other diagnostic findings.

Applications

• Ovarian reserve assessment
• Fertility evaluation support
• IVF and assisted reproductive technology planning
• Reproductive hormone analysis
• PCOS evaluation support
• Ovarian function monitoring
• Diagnostic laboratory testing for fertility clinics

• AMH testing helps estimate the remaining egg supply in the ovaries. A higher AMH value may suggest a higher ovarian reserve, while a lower AMH value may suggest reduced ovarian reserve. However, AMH does not measure egg quality and cannot guarantee natural pregnancy outcomes.
• In fertility clinics, AMH testing is used to help doctors understand how a patient may respond to ovarian stimulation medicines. This can support individualized fertility treatment planning, including IVF protocols.
• High AMH levels may be associated with polycystic ovary syndrome because PCOS often involves a higher number of small ovarian follicles. AMH testing may support PCOS evaluation, but AMH alone cannot diagnose PCOS.
• AMH levels decline with age and may be used in some clinical settings to evaluate ovarian function and support assessment of early or premature menopause. However, AMH cannot accurately predict the exact timing of menopause.

The AMH Rapid Test Device (Serum) uses a fluorescence-based immunoassay principle. Fluorescence immunoassay technology is valued in diagnostic testing because it supports sensitive marker detection and quantitative result interpretation when used with a compatible analyzer system.

Benefits

• Fluorescence-based AMH detection
• Quantitative serum AMH testing support
• Suitable for professional diagnostic laboratories
• Supports ovarian reserve assessment
• Useful for reproductive hormone evaluation
• Supports fertility and IVF clinic workflows
• Professional diagnostic solution for international healthcare markets

The correct specimen for the AMH Rapid Test Device is serum. Proper sample collection, serum separation, storage, and handling are important for reliable test performance.

Guidance

• Use serum specimen only as specified
• Follow approved blood collection procedures
• Separate serum according to laboratory protocol
• Avoid hemolyzed, contaminated, or improperly stored specimens
• Use calibrated and compatible fluorescence analyzer systems
• Bring test components to recommended temperature before use if required
• Follow the LARKSOIS Pharma product insert carefully

Note

The AMH Rapid Test Device should be used only by trained healthcare or laboratory professionals in professional diagnostic environments.

Steps

• Bring the test device, serum sample, and reagents to the recommended testing temperature
• Open the sealed test package only when ready to perform the test
• Prepare the serum specimen according to the product insert
• Apply the required amount of serum or prepared sample to the test device
• Use the compatible fluorescence analyzer system where required
• Allow the test reaction to complete within the instructed time
• Read and report the result according to the approved interpretation guidance

Note

The exact procedure should follow the official LARKSOIS Pharma product insert and compatible fluorescence analyzer instructions.

Positive

Higher AMH levels may suggest a larger ovarian follicle pool or may support further evaluation for conditions such as PCOS when interpreted with symptoms, ultrasound findings, and other hormone tests.

Negative

Lower AMH levels may suggest reduced ovarian reserve, but AMH alone does not predict whether pregnancy can or cannot occur. Age, egg quality, ovulation, sperm health, and other reproductive factors also matter.

Invalid

If the analyzer, control system, or test device indicates an invalid result, repeat testing should be performed according to the product insert and laboratory quality-control procedure.

Instructions

• Store according to the manufacturer’s product label and package insert
• Protect from excessive heat, moisture, direct sunlight, and contamination
• Keep the test device sealed until use
• Do not use expired test devices
• Do not use damaged or contaminated packaging
• Use calibrated and compatible fluorescence analyzer systems
• Dispose of used diagnostic materials according to laboratory safety rules

Instructions

• For professional in vitro diagnostic use only
• Not intended for self-diagnosis or self-treatment decisions
• AMH results must be interpreted with patient age and medical history
• Use results with menstrual status, ultrasound findings, and other hormone tests
• AMH cannot independently confirm whether a person can or cannot become pregnant
• AMH does not measure egg quality
• Follow local regulatory and clinical diagnostic guidelines

LARKSOIS Pharma focuses on internationally acceptable diagnostic product standards, dependable quality, and professional-use healthcare solutions. The AMH Rapid Test Device (Serum) is suitable for clinical environments where accurate reproductive hormone testing is required.

Advantages

• Fluorescence-based AMH detection
• Serum specimen compatibility
• Suitable for fertility and IVF clinics
• Supports ovarian reserve assessment
• Useful in reproductive hormone evaluation
• Helps clinicians make informed treatment decisions
• Professional diagnostic solution for international healthcare markets